ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Thymoglobulin Plus Basiliximab vs Basiliximab as Induction Therapy in Deceased Donor Kidney Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: 1-Year Results of a Prospective Clinical Trial

E. Favi, G. Spagnoletti, N. Silvestrini, M. Salerno, J. Pedroso, J. Romagnoli, F. Citterio

Surgery - Renal Transplantation, Catholic University, Rome, Italy

Meeting: 2013 American Transplant Congress

Abstract number: C1339

Related Abstracts
  • Extended-Release Tacrolimus Plus Everolimus vs Extended-Release Tacrolimus Plus Micophenolate Mofetil in Primary Deceased Donor Kidney Transplant Recipients: 1-Year Results of an Open Label, Randomized Phase 2 Clinical Trial
  • Steroid Avoidance with Alemtuzumab Induction and Tacrolimus Monotherapy Gives Similar Outcomes to Basiliximab Induction with Tacrolimus / Mycophenolate Maintenance at Three Years

Purpose. The aim of this prospective, exploratory, single center study in kidney transplantation was to compare two immunosuppressive induction regimens: thymoglobulin plus basiliximab (THY) versus basiliximab (BAX).

Methods. Sixty deceased donor kidney transplant recipients were prospectively assigned to THY (30 pts) or BAX (30 pts) and followed up for 1 year. As induction therapy patients assigned to THY received a combination of thymoglobulin (50 mg/day iv from day 0 to day 3, total dose 200 mg) and basiliximab (20 mg iv on day 0 and day 4), while recipients allocated to BAX received only basiliximab (20 mg iv on day 0 and day 4). As maintenance all patients received tacrolimus, MMF and steroids. Steroids in the THY group were selectively withdrawn after 6 months in patients with no previous transplantation, no acute rejection episodes, serum creatinine < 2 mg/dL and proteinuria < 300 mg/24 h.

Results. Demographic characteristics of patients were similar in the two groups. Efficacy and safety parameters after 1 year of follow up are summarized in the table.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Favi E, Spagnoletti G, Silvestrini N, Salerno M, Pedroso J, Romagnoli J, Citterio F. Thymoglobulin Plus Basiliximab vs Basiliximab as Induction Therapy in Deceased Donor Kidney Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: 1-Year Results of a Prospective Clinical Trial [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/thymoglobulin-plus-basiliximab-vs-basiliximab-as-induction-therapy-in-deceased-donor-kidney-transplant-recipients-treated-with-tacrolimus-and-mycophenolate-mofetil-1-year-results-of-a-prospective-cli/. Accessed January 17, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.
  THY BAX p
Patients (#) 30 30  
Patient survival (%) 100 100 ns
Graft survival (%) 100 97 ns
BPAR (%) 10 14 ns
Serum creatinine (mg/dL) 1.5±0.4 1.4±0.4 ns
Creatinine clearance (mL/min) 55±20 60±19 ns
Proteinuria (g/24h) 0.1±0.2 0.2±0.4 ns
Hemoglobin (g/dL) 12.7±1.4 13.6±1.7 ns
WBC count (cellx10^3/mL) 6.7±2.5 6.5±1.3 ns
Platelet count (cellx10^3/mL) 274±153 197±45 <0.05
Total cholesterol (mg/dL) 209±53 210±38 ns
Triglycerides level (mg/dL) 185±22 168±125 ns
Systolic blood pressure (mmHg) 125±13 129±13 ns
Diastolic blood pressure (mmHg) 73±7 78±10 <0.05
Dislipidemia on treatment (%) 29 21 ns
NODAT (%) 3 7 ns
CMV disease (%) 0 0 ns
PVAN (%) 0 0 ns
Tacrolimus C0 (ng/mL) 6.5±1.6 8.3±3.3 <0.05
Tacrolimus C2 (ng/mL) 11.3±4.9 14.4±5.6 <0.05
MMF daily dose (mg) 989±53 947±158 ns
Steroids daily dose (mg) 2.4±2.1